LONDON (Reuters) – Shire will start making a genetic disease medicine itself after it was hit by supply problems, the London-listed firm said on Friday as it reported a sharp rise in profit.
Source: Reuters Health News
LONDON (Reuters) – Shire will start making a genetic disease medicine itself after it was hit by supply problems, the London-listed firm said on Friday as it reported a sharp rise in profit.
Source: Reuters Health News